From Sample to Insight: Technologies Driving the Future of Precision Oncology Assays
non-small cell lung cancer (NSCLC), multiplexed qPCR panels can assess EGFR, KRAS, BRAF, and ALK alterations in parallel, accelerating time to result and guiding targeted therapy decisions from a single run. 4 This expanded capacity enables broad mutation screening in tissue-limited samples, offering a
faster, more affordable, and simpler alternative to NGS—ideal for clinical labs and time-sensitive or resource-limited settings. As the technology evolves, it will continue to expand diagnostic coverage while preserving the speed, affordability, and regulatory familiarity that make it an attractive alternative to sequencing.
Performance Insight Meridian’s MDX092 Air-Dryable™ Direct DNA qPCR Blood mix successfully amplified target DNA down to 10 copies, even in the presence of 20% heparin- plasma. In contrast, comparator mixes did not detect the target at this low level. These findings underscore the importance of inhibitor-tolerant chemistry for enabling sensitive mutation detection in real-world clinical samples.
Reagent Solutions for Oncology qPCR Applications qPCR’s continued dominance in oncology depends on more than just platform design—it requires reagent systems that deliver consistency, sensi- tivity, and flexibility under real-world conditions. Meridian provides a portfolio of high-performance qPCR enzymes and master mixes engineered to meet the evolving demands. Their reagents are
Enzymes Optimized for Clinical Sample Types
To address common barriers like sample inhibi- tion and DNA degradation, Meridian’s next-gen- eration DNA polymerases are engineered to perform reliably with low-input inhibitor-rich clinical matrices, including formalin-fixed paraf- fin-embedded (FFPE) tissue, plasma, and other challenging sample types. In one evaluation using 20% heparin-plasma ( Figure 2 ), a common yet inhibitory matrix in blood-derived liquid
optimized for clinical sample types and diag- nostic workflows, supporting applications such as companion diagnostics, MRD monitoring, and high-throughput mutation screening.
26 | GENengnews.com
Powered by FlippingBook